Question 1

What is a cash flow statement?

Accepted Answer

A cash flow statement tracks the actual cash moving in and out of a company during a period. It's divided into three sections: operating activities (core business), investing activities (assets and investments), and financing activities (debt and equity). Unlike the income statement, it shows real cash rather than accounting profits.

Question 2

What is operating cash flow?

Accepted Answer

Operating cash flow is the cash generated from a company's core business operations. It adjusts net income for non-cash items like depreciation and changes in working capital. Strong operating cash flow indicates the business can fund operations without external financing.

Question 3

What is free cash flow (FCF)?

Accepted Answer

Free cash flow is operating cash flow minus capital expenditures. It represents the cash available for dividends, share buybacks, debt repayment, or reinvestment. FCF is considered one of the most important metrics for evaluating a company's financial health.

Question 4

What are capital expenditures?

Accepted Answer

Capital expenditures (CapEx) are funds spent on acquiring or maintaining physical assets like property, equipment, and technology. CapEx appears in the investing activities section and is subtracted from operating cash flow to calculate free cash flow.

Question 5

How is CTNM's cash generation trending?

Accepted Answer

Review Contineum Therapeutics's operating cash flow and free cash flow figures in the quarterly and annual data above. Consistent growth in operating cash flow relative to net income indicates high-quality earnings.

Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Operating Activities
Net Income	-59.98	-42.26	22.72	-24.25	-29.00
Depreciation & Amortization	0.32	0.26	0.20	0.33	0.33
Stock Based Compensation	10.04	6.80	2.22	1.93	1.75
Change in Working Capital	-6.04	5.33	-1.02	-1.27	0.11
Change in Accounts Payable	-0.87	1.14	0.00	-0.23	-0.11
Change in Other Working Capital	-6.04	4.19	-1.02	-1.27	0.16
Other Operating Activities	0.34	-2.98	-4.76	3.14	0.16
Net Cash from Operating Activities	-55.31	-32.85	19.35	-20.12	-26.27
Investing Activities
Capital Expenditures	-0.23	-0.51	-0.41	-0.12	-0.17
Acquisitions	0.00	0.02	0.00	0.00	0.00
Purchases of Investments	-162.50	-226.41	-141.87	-64.70	-66.78
Sales/Maturities of Investments	159.02	157.16	76.71	87.12	1.98
Net Cash from Investing Activities	-3.71	-69.74	-65.57	22.30	-64.97
Financing Activities
Debt Repayment	0.00	0.00	-3.75	-1.25	0.00
Common Stock Issued	112.94	108.21	0.00	0.02	0.00
Common Stock Repurchased	0.00	0.00	-0.03	0.00	0.00
Other Financing Activities	-0.26	0.79	59.95	0.02	79.84
Net Cash from Financing Activities	112.69	109.00	56.18	-1.24	79.84
Summary
Net Change in Cash	53.66	6.42	9.96	0.94	-11.40
Cash at Beginning of Period	21.94	15.53	5.57	4.63	16.03
Cash at End of Period	75.60	21.94	15.53	5.57	4.63
Free Cash Flow	-55.54	-33.36	18.94	-20.24	-26.43
Supplemental Disclosures
Interest Paid	0.00	0.00	0.15	0.23	0.22
Income Taxes Paid	0.00	0.00	0.45	0.00	0.00

Contineum Therapeutics (CTNM) Cash Flow Statement

Contineum Therapeutics Cash Flow Statement Analysis

Frequently Asked Questions About Contineum Therapeutics Cash Flow

Free Cash Flow (FCF)

FCF Per Share

Cash Flow to Debt

Dividend Payout Ratio

EBITDA

Return on Invested Capital (ROIC)